{"id":"neoadjuvant-chemotherapy-interval-debulking-surgery","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Surgical complications"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a combined treatment approach where chemotherapy is administered first to reduce tumor burden and improve resectability, followed by surgical cytoreduction after a treatment interval. The chemotherapy sensitizes tumors and reduces their size, allowing surgeons to achieve more complete tumor removal during the subsequent debulking procedure, which aims to maximize overall survival in advanced ovarian cancer.","oneSentence":"Neoadjuvant chemotherapy shrinks ovarian tumors before surgical removal, followed by interval debulking surgery to resect remaining disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:25.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced ovarian cancer (Stage III-IV) unsuitable for primary cytoreduction"}]},"trialDetails":[{"nctId":"NCT06504147","phase":"PHASE2","title":"A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery","status":"RECRUITING","sponsor":"Oncoinvent Solutions AS","startDate":"2024-06-15","conditions":"Peritoneal Carcinomatosis, Ovarian Cancer","enrollment":114},{"nctId":"NCT04454450","phase":"NA","title":"Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-06-22","conditions":"Ovarian Cancer, High Grade Ovarian Serous","enrollment":10},{"nctId":"NCT07432594","phase":"PHASE2","title":"Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03-01","conditions":"High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers, Primary Peritoneal Cancer","enrollment":82},{"nctId":"NCT03579394","phase":"NA","title":"Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2018-10-19","conditions":"Ovarian Cancer Stage IV, Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IIIb","enrollment":211},{"nctId":"NCT07382479","phase":"NA","title":"NeoAdjuvant ChemoTherapy With KELIM Guided Interval vs. Delayed Interval Debulking Surgery","status":"NOT_YET_RECRUITING","sponsor":"Aristotle University Of Thessaloniki","startDate":"2026-04-01","conditions":"Ovarian Cancer","enrollment":485},{"nctId":"NCT07366242","phase":"","title":"Prognostic Value of (DHODH) Expression in (HGSOC): A Comparative Study Between Neoadjuvant and Adjuvant Chemotherapy Settings","status":"NOT_YET_RECRUITING","sponsor":"Heba Ahmed Mohamed","startDate":"2026-06-01","conditions":"HGSOC","enrollment":72},{"nctId":"NCT05080946","phase":"EARLY_PHASE1","title":"Using Aspirin to Improve Immunological Features of Ovarian Tumors","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-11-02","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":100},{"nctId":"NCT06964165","phase":"PHASE2","title":"A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)","status":"TERMINATED","sponsor":"Tesaro, Inc.","startDate":"2022-04-14","conditions":"Ovarian Neoplasms","enrollment":36},{"nctId":"NCT07125391","phase":"PHASE2","title":"Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer","status":"RECRUITING","sponsor":"Bai-Rong Xia","startDate":"2025-06-20","conditions":"Ovarian Cancer","enrollment":40},{"nctId":"NCT03574779","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2018-11-15","conditions":"Ovarian Neoplasms","enrollment":77},{"nctId":"NCT07058753","phase":"NA","title":"Prehabilitation in Ovarian Cancer Patients During Chemiotherapy Before Cytoreductive Surgery.","status":"ENROLLING_BY_INVITATION","sponsor":"Medical University of Silesia","startDate":"2025-07-01","conditions":"Ovarian Cancer","enrollment":100},{"nctId":"NCT04498117","phase":"PHASE3","title":"Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanariaBio Inc.","startDate":"2020-08-25","conditions":"Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer","enrollment":615},{"nctId":"NCT07023484","phase":"PHASE2","title":"Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-05-22","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma","enrollment":126},{"nctId":"NCT07022535","phase":"PHASE2","title":"Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2024-05-28","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":18},{"nctId":"NCT06883409","phase":"NA","title":"Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer","status":"RECRUITING","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2022-05-19","conditions":"Ovarian Neoplasms","enrollment":33},{"nctId":"NCT05200260","phase":"PHASE2","title":"Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer","status":"RECRUITING","sponsor":"Shanghai Gynecologic Oncology Group","startDate":"2022-07-13","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma","enrollment":220},{"nctId":"NCT02859038","phase":"PHASE3","title":"Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Gynecologic Oncology Group","startDate":"2016-08","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma","enrollment":489},{"nctId":"NCT04701645","phase":"PHASE1","title":"Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":20},{"nctId":"NCT04846933","phase":"NA","title":"Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC","status":"RECRUITING","sponsor":"Turku University Hospital","startDate":"2012-02-01","conditions":"High Grade Ovarian Serous Adenocarcinoma, High Grade Serous Carcinoma","enrollment":200},{"nctId":"NCT06385912","phase":"","title":"Systematic Lymphadenectomy During Interval Debulking Surgery in Advanced Epithelial Ovarian Cancer","status":"COMPLETED","sponsor":"Tongji Hospital","startDate":"2006-07-01","conditions":"Ovarian Cancer, Postoperative Complications, Neoadjuvant Therapy","enrollment":1090},{"nctId":"NCT06223763","phase":"","title":"SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery","status":"UNKNOWN","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2024-01-01","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasms","enrollment":5000},{"nctId":"NCT05371301","phase":"PHASE3","title":"Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-07-16","conditions":"Ovarian Cancer","enrollment":200},{"nctId":"NCT03378128","phase":"NA","title":"Debulking Surgery in Ovarian Cancer","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2018-01-12","conditions":"Malignant Neoplasm of Ovary, Malignant Neoplasm of Fallopian Tube, Malignant Neoplasm of Peritoneum","enrollment":50},{"nctId":"NCT03607955","phase":"PHASE1","title":"Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2021-06-30","conditions":"Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer","enrollment":""},{"nctId":"NCT04815408","phase":"PHASE2","title":"PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-04-01","conditions":"Ovarian Cancer, Neoadjuvant Chemotherapy, Anti-PD-1","enrollment":40},{"nctId":"NCT02249013","phase":"PHASE2","title":"Short-course HIPEC in Advanced Epithelial Ovarian Cancer","status":"COMPLETED","sponsor":"Professor Fernando Figueira Integral Medicine Institute","startDate":"2015-02","conditions":"Ovarian Cancer","enrollment":15},{"nctId":"NCT04747717","phase":"NA","title":"Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer","status":"UNKNOWN","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2020-10-01","conditions":"Ovarian Cancer","enrollment":30},{"nctId":"NCT01519869","phase":"PHASE2","title":"Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma","status":"COMPLETED","sponsor":"Rachel Miller","startDate":"2012-03","conditions":"Primary Peritoneal Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma","enrollment":28},{"nctId":"NCT01461850","phase":"PHASE3","title":"Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2011-10-01","conditions":"Stage IIIC Ovarian Cancer","enrollment":171},{"nctId":"NCT03899610","phase":"PHASE2","title":"A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2019-07-04","conditions":"Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV","enrollment":24},{"nctId":"NCT04515602","phase":"PHASE3","title":"Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Gynecologic Oncology Group","startDate":"2021-01","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma","enrollment":410},{"nctId":"NCT04261465","phase":"PHASE2","title":"NUVOLA TRIAL Open-label Multicentre Study","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2019-12-01","conditions":"High Grade Serous Ovarian Cancer","enrollment":35},{"nctId":"NCT03448354","phase":"NA","title":"Comparative Effectiveness of HIPEC Following Interval Debulking Surgery in Patients With Advanced-stage Ovarian Cancer","status":"UNKNOWN","sponsor":"Ajou University School of Medicine","startDate":"2017-10-26","conditions":"Ovarian Cancer","enrollment":204},{"nctId":"NCT03491033","phase":"","title":"Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2017-08-28","conditions":"Advanced-stage Ovarian Cancer","enrollment":250},{"nctId":"NCT03180177","phase":"PHASE3","title":"Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer","status":"UNKNOWN","sponsor":"Shu-Zhong Cui","startDate":"2018-03-01","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma","enrollment":263},{"nctId":"NCT00331422","phase":"PHASE2","title":"Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-10","conditions":"Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer","enrollment":7},{"nctId":"NCT01905163","phase":"PHASE2","title":"Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients","status":"COMPLETED","sponsor":"Centre Jean Perrin","startDate":"2013-08","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cavity Cancer","enrollment":47},{"nctId":"NCT02324595","phase":"PHASE2","title":"Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: a Feasibility Study","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2013-12","conditions":"Stage IV Ovarian Carcinoma, Effects of Chemotherapy, Peritoneal Cavity Cancer","enrollment":30},{"nctId":"NCT00008138","phase":"PHASE2","title":"S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2001-03","conditions":"Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer","enrollment":62},{"nctId":"NCT01724944","phase":"PHASE1, PHASE2","title":"LYmphadenectomy After NeoAdjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Catholic University of the Sacred Heart","startDate":"2011-02","conditions":"Advanced Ovarian Cancer (Stage III or IV) After Neoadjuvant Chemotherapy","enrollment":65},{"nctId":"NCT00715286","phase":"PHASE3","title":"Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences","startDate":"2001-11","conditions":"Ovarian Carcinoma","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Neoadjuvant chemotherapy + Interval Debulking Surgery","genericName":"Neoadjuvant chemotherapy + Interval Debulking Surgery","companyName":"Catholic University of the Sacred Heart","companyId":"catholic-university-of-the-sacred-heart","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Neoadjuvant chemotherapy involves the use of Paclitaxel and Carboplatin in combination with Olaparib, a granulocyte colony-stimulating factor receptor agonist, to treat conditions such as High Grade Serous Ovarian Cancer and Epithelial Ovarian Cancer. Interval Debulking Surgery is a surgical procedure that may be performed after neoadjuvant chemotherapy to remove as much of the tumor as possible.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}